Assess whether pediatric studies are necessary or waivable (86ca82)

Situation

Pediatric studies are necessary sits with 505(b)(2) development lead because a pediatric ethicist objecting to the proposed design hit a labeling team facing a boxed-warning debate. Evidence is 505(b)(2) literature-to-product bridge table; write the Pharma & Life Sciences CMC and Development Pathways option that extract can carry.

Decision

505(b)(2) development lead in a labeling team facing a boxed-warning debate must choose Pediatric studies are necessary / Waivable using 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• Authorize Pediatric studies are necessary now; 505(b)(2) literature-to-product bridge table already has the discriminator after a pediatric ethicist objecting to the proposed design.
• Keep Waivable in force until 505(b)(2) literature-to-product bridge table is completed after a pediatric ethicist objecting to the proposed design for 505(b)(2) development lead.
• Treat 505(b)(2) literature-to-product bridge table as Pediatric studies are necessary because both readings appear after a pediatric ethicist objecting to the proposed design.
• Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the page pediatric studies are necessary turns on in 505(b)(2) literature-to-product bridge table.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a pediatric ethicist objecting to the proposed design and write the one fact that would move pediatric studies are necessary for 505(b)(2) development lead.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design). The follow-on CMC and Development Pathways action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.